D.E. Shaw & Co’s VYNE Therapeutics VYNE Stock Holding History

D.E. Shaw & Co’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-395	Closed	-$231K	–	4007
2018 Q2	$231K	Buy	+395	New	+$307K	﹤0.01%	3491

Other funds holding VYNE

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

D.E. Shaw & Co's VYNE Position: Q3 2018 in Review

D.E. Shaw & Co sold out of VYNE Therapeutics (VYNE) in Q3 2018, closing a stake of 395 shares — an estimated $231K sold.

D.E. Shaw & Co first reported a position in VYNE in Q2 2018 and held it in 1 quarter. The position peaked at $231K in Q2 2018. 52 funds tracked by Wall St. Rank hold VYNE as of Q3 2018.

D.E. Shaw & Co reported no remaining VYNE Therapeutics position as of Q3 2018 after selling out during the quarter.
D.E. Shaw & Co sold 395 VYNE Therapeutics shares in Q3 2018, an estimated $231K.
D.E. Shaw & Co first reported a position in VYNE Therapeutics in Q2 2018 and held it in 1 quarter.
D.E. Shaw & Co's VYNE Therapeutics position peaked at $231K in Q2 2018.
52 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q3 2018.

Based on D.E. Shaw & Co's 13F filing for Q3 2018, filed 14 Nov 2018.